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Title: Pharmacokinetics of Mycophenolate Mofetil in adult patients with lupus nephritis with 
a special reference to the measurement of free MPA and saliva MPA. 
Background: - Mycophenolate Mofetil (MMF), the immunosuppressive agent, is commonly 
used to treat renal transplant patients and patients with other autoimmune diseases such as 
Systemic Lupus Erythematosus (SLE). Due to the high inter-dose, inter-patient variability in 
drug exposure, therapeutic drug monitoring (TDM) has proved extremely beneficial in 
individualizing the MMF therapy. Measurement of Mycophenolic Acid (MPA) area under the 
curve (AUC0-12 hr) involves collection of multiple blood specimens, over 12 hours.  
 
Objectives: (i) To establish the pharmacokinetics of MMF in patients with lupus nephritis 
(ii) To develop a limited sampling strategy (LSS) for the estimation of MPA 
AUC0-12 hr. 
(iii) To determine if any correlation between free MPA in plasma and saliva 
MPA concentration. 
 
Methods: Plasma specimens from 30 patients with lupus nephritis were prospectively 
collected at the respective time points: trough (prior to MMF dose), then at 0.5, 1, 1.5, 2, 2.5, 
3, 4, 6, 8 and 12 hours after patients had taken MMF. Total MPA AUC 0-12 hr was estimated 
using high performance liquid chromatography (HPLC with UV detection).  Saliva and free 
MPA concentrations were collected at 1 hour post-dose, measured and their correlation was 
compared. Limited sampling strategies with acceptable correlation coefficients (R2), bias and 
precision were developed by stepwise multiple regression analysis. The predictive 
performance of the LSS was validated using bootstrap validation.  Pharmacokinetic 
parameters were analysed using Pmetrics software for R. 
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Results: The observed MPA AUC0-12 hr ranged from 19.52 to 67.67 mg.h/L with a mean of 
45.12 mg.h/L. The mean Cmax and Tmax were 16.703 mg.h/L and 1.08 h respectively. The 
mean dose per kg body weight of MMF prescribed was 26.47 mg/kg. The best LSS model 
included concentrations at time points 0, 1, 2 and 4 (C0, C1, C2, C4) (multiple R2=0.926). The 
final model validated post bootstrap is as follows:  
MPA AUC0-12 hr= 12.3376+ (2.9013XC0) + (0.8305XC1) + (0.7945XC2) + (4.5156XC4). 
Calculated bias and imprecision for the LSS were -0.13 and 7.09 % respectively. 
The observed correlation between free MPA in plasma and saliva MPA was poor overall 
(r=0.085, p>0.05). However good correlation (r= 0.790, p=0.02) was observed in the low 
albumin group (n=8). 
 
Conclusion: This study has, for the first time, described the pharmacokinetics of MMF in 
adult Indian patients with lupus nephritis and the developed 4 point LSS is an accurate 
measure of the total 12-hour MPA AUC0-12 hr with favourable bias and precision. 
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 Systemic Lupus Erythematosus (SLE) is an autoimmune disorder which is 10 times 
more frequent in women than in men.(1,2) Traditionally used drugs for SLE like 
Cyclophosphamide were effective in controlling the symptoms but had a lot of side effects as 
compared to newer drugs like Mycophenolate Mofetil (MMF). The most common systemic 
manifestations of the disease include dermatological and renal manifestations.(1,3,4)  
 Lupus nephritis is the renal manifestation of SLE which is more common and severe 
in African Americans followed by the Asians.(5,6) Caucasians are relatively less affected. 
The T-cells as well as the pro-inflammatory cytokines like transforming growth factor β 
(TGF-β), Il-1, Il-18 and interferon α (IFN α) are the most important factors responsible for 
the destruction of the glomeruli.(5) As the disorder is of autoimmune origin, 
immunosuppressants have been found to be most effective against lupus nephritis. Previously 
used immunosuppressants include cyclophosphamide and azathioprine but, even though they 
were effective in controlling symptoms and clinical flares, they had a lot of side effects. In 
the early 2000’s, the immunosuppressant mycophenolic acid was tried in SLE and lupus 
nephritis and was found to be as efficacious as cyclophosphamide with lesser side 
effects.(7,8) The current EULAR (European League against Rheumatism) recommendations 
include mycophenolate as first line therapy in patients with higher stages of lupus nephritis 
(stage III, IV and V).(9)Currently, there is considerable interest in developing biological 
agents like rituximab and belimumab for the treatment of SLE.(10) However, they do not 
have any added benefit plus their high costs are a deterrent to their use, especially in low 
middle income countries like ours. 
 Mycophenolate mofetil (MMF) is one of the dosage forms of mycophenolic acid 
(MPA). It is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) in 
purine biosynthesis. The T-lymphocytes are highly susceptible to its action as they are highly 
reliant on the de novo pathway for synthesis of purines while other cells recover as they 
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possess an alternative pathway for the same. MMF was originally developed for clinical use 
in renal transplant patients and has now become the mainstay in the treatment of renal 
transplant patients due to its comparable efficacy and lesser toxicity.(11) Since the T-cells are 
the major cells implicated in the pathophysiology of lupus nephritis, this drug should be 
effective against lupus nephritis as well. 
 However, mycophenolate needs to be monitored therapeutically due to its high (10 
fold) inter-patient variability in pharmacokinetics.(12) It is generally agreed that MPA dose 
should be titrated in renal transplant patients to maintain an MPA AUC0-12 hr (Area under the 
concentration-time curve up to 12 hours post dose depicting MPA exposure) between 30-60 
mg.h/L to avoid acute rejection as well as have lesser side effects due to the 
immunosuppression.(12–14) 
 The AUC measurement requires collection of many blood samples (often more than 
8) and it requires the patient to be in the laboratory for the whole duration of sampling (for 
MPA it is 12 hours). Though trough (immediate pre-dose) concentrations have been used to 
indicate drug exposure for other therapeutic agents, for MPA, it may not correlate well with 
the MPA AUC0-12 hr.(15) Therefore, a robust equation needs to be developed based on limited 
samples (Limited sampling strategy (LSS)) so as to reduce costs and lead to a shorter hospital 
stay for the patients.  
The pharmacokinetics of MMF in transplant patients is very different from that seen in 
autoimmune diseases like SLE.(12) Some reasons contributing to this would be unpredictable 
absorption in the early post-transplant period, different co-medications and differences in 
albumin, urea and GFR between transplant and SLE patients. So limited sampling strategy 
equations developed in transplant patients cannot be extrapolated to a different cohort of SLE 
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patients. Therefore one of the objectives of our study is to develop and validate a reliable, 
clinically viable LSS for patients with lupus nephritis prescribed Mycept® brand of MMF. 
There have been a few studies describing the pharmacokinetics of mycophenolate 
mofetil in patients with lupus nephritis from various different parts of the world. To date, 
there is no study done in Indian patients with lupus nephritis. Another objective of our study 
is to elucidate pharmacokinetics of mycophenolate mofetil in Indian patients with lupus 
nephritis. 
In SLE patients with a higher probability of having lower albumin, it is the free 
(unbound pharmacologically active) drug concentration that is important for its action and 
may be more clinically relevant as compared to the total MPA (bound and free) 
concentrations.(16,17) The problem with measuring free MPA concentrations is that it 
requires the use of a biological membrane filter which makes monitoring free MPA more 
costlier than monitoring total MPA concentrations. Human saliva is an ultrafiltrate and has 
the potential to be a viable alternative to the measurement of free MPA.  It is easy to collect 
and is non-invasive.(18) We also intended to correlate saliva, total and plasma free MPA 
concentrations at one hour after MMF. And to examine the possibility of developing an 
equation to estimate free MPA from either saliva or total MPA concentrations. 
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Aims 
“To establish pharmacokinetics of oral mycophenolate mofetil (MMF) in Indian adult 
patients with lupus nephritis.” 
Objectives 
(i) To validate the assay of free MPA and saliva MPA measurement using high 
performance liquid chromatography. 
(ii) To measure the exposure to MMF as mycophenolic acid area under the curve (Total 
MPAAUC0-12 hr) in lupus nephritis patients.  
(iii) To develop and validate a limited sampling strategy equation to estimate total MPA 
AUC 0-12 hr. 
(iv) To study basic pharmacokinetic parameters and to create a population 
pharmacokinetic model , using the Pmetrics package  
(v) To study if any correlation exists between saliva MPA, free MPA and total MPA 
concentrations at one hour after MMF. 
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Systemic Lupus Erythematosus – The Disease 
Description 
 Systemic Lupus Erythematosus (SLE) is a multisystem chronic autoimmune disorder 
that can affect most organs of the body. (1) The more common manifestations of the disease 
include dermatological, musculoskeletal and renal manifestations.(1,3,4) 
  
Aetiology 
The aetiology of SLE is still unknown other than the fact that it is an autoimmune disorder. 
However SLE is thought to have a genetic basis apart from various environmental factors 
which are depicted in the flowchart below.(19) 
Figure 1: Aetiology of SLE 
  Around 33 % of the patients have recurrent flares of SLE and pregnant women are at 
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a higher risk of flares of SLE. The risk of flares is equal in all the three trimesters of 
pregnancy.(20) 
 
Epidemiology 
Studies have shown that there is marked epidemiological variation with respect to race, age, 
sex and environmental factors among the different Asian countries. (4) Females (in the child 
bearing age) are 12 times more likely to be affected than males.(2)The average prevalence in 
Asian countries was found to be in the range of 30-50 per 100000 population.(4) However, 
the single largest study from India reported a point prevalence of only 3.2 per 100000 
population.(21) It is also reported that there is varying degrees of renal involvement in SLE in 
more than 50 % of cases.(4) There were a few reported cases of protein losing enteropathy in 
SLE in India which can present as nephrotic syndrome with low serum albumin.(22) 
Scoring systems 
 SLEDAI (SLE Disease Activity Index) is the most common scoring system used to 
evaluate SLE disease intensity and evolution.(23)The SLEDAI scoring actually gives 
different weights for the different signs and symptoms of SLE like vasculitis, seizures, 
arthritis, myositis, visual disturbances, proteinuria, haematuria etc.  A change in the SLEDAI 
score > 3 indicates a mild to moderate flare while a change in the SLEDAI score >12 
indicates a severe flare. Other scoring systems include the SLE scoring system (SIS) as well 
as the ACR criteria. 
Treatment of SLE 
Many different drugs have been used to tackle SLE with limited success including 
hydroxychloroquine, corticosteroids, methotrexate, azathioprine and cyclosporine. However, 
MPA (Mycophenolic acid) is being increasingly preferred over the others because of its 
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improved safety profile. There are a few meta-analysis done to see the efficacy of 
mycophenolate over other drugs like cyclophosphamide and azathioprine and most of them 
conclude that mycophenolate is equally efficacious and has lesser side effects.(7,8) 
 
Lupus nephritis 
Background with Staging 
 Lupus nephritis is a kidney inflammation caused by SLE, an autoimmune disease. The 
World Health Organization (WHO) staging of lupus nephritis is universally accepted world 
over. It has been modified and the current accepted classification is given by the International 
Society of nephrology/Renal Pathology Society (ISN/RPS) (2003) classification of lupus 
nephritis.(24) The current categories of lupus nephritis include:(24) 
Class I – Minimal mesangial lupus nephritis 
 Normal looking glomeruli by light microscopy but immunofluorescence microscope 
shows mesangial immune deposits. 
Class II – Mesangial proliferative lupus nephritis 
 Mesangial proliferation of any degree on light microscope with mesangial immune 
deposits 
Class III – Focal lupus nephritis 
 Focal, segmental or global endo- or extra-capillary glomerulonephritis involving less 
than half of the glomeruli with focal sub-endothelial deposits.  
Class IV – Diffuse lupus nephritis 
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 Involvement of more than half of the glomeruli typically with diffuse sub-endothelial 
deposits with or without mesangial alterations.  
Class V – Membranous lupus nephritis 
 Global or segmental sub-epithelial immune deposits or their sequelae, with or without 
mesangial alterations. Class V patients typically have advanced glomerular sclerosis 
Class VI – Advanced sclerosis lupus nephritis 
 Involvement of >90 % of the glomeruli which are globally sclerosed without any 
residual activity. 
Epidemiology 
 Most cases of SLE develop lupus nephritis early in the course of the disease. A vast 
majority of those patients who develop lupus nephritis are less than 55 years of age with 
children being much more commonly affected as compared to the elderly. There are also 
racial differences in the presentation of lupus nephritis. African Americans as well as Asians 
seem to have more severe clinical symptoms as compared to Caucasians.(5,6) 
  
Pathophysiology 
 Multiple mechanisms are involved in the pathophysiology of lupus nephritis including 
both the systemic as well as local factors.(5,11) However, the most prominent 
pathophysiological characteristic of lupus nephritis happens to be immune complex 
deposition in the glomeruli. This initiates a cascade of events that lead to glomerular disease. 
T-cells are probably the most conspicuous cells seen in both humans as well as mouse models 
of lupus nephritis. TGF-β (transforming growth factor β) as well as IL-4 (Interleukin 4) 
seems to be closely related to the pathological features and these chemicals are secreted as a 
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part of the Th1 response of the T-helper cells. Apart from the lymphocytes, even the myeloid 
cells seem to play a major role in the pathophysiology of lupus nephritis. The myeloid 
differential cells infiltrate the kidney and are thought to release pro-inflammatory cytokines 
like TGF-β, Il-1, Il-18 and interferon α (IFN α). However the pro-inflammatory cytokines 
seem to play a major role in the pathogenesis of lupus nephritis, be it antigen presentation at 
the local lymph nodes or the local inflammation.(5) 
  
Signs and symptoms 
 In a study done in eastern Indian patients, it was found that the commonest symptoms 
included arthritis, rash and fever.(6) They reported that the mean duration of symptoms 
before diagnosis was 13.9 months. Around 42% of the patients had nephrotic range 
proteinuria. The mean reported serum albumin and creatinine values were 3.09 g/dl and 1.62 
mg/dl. 82 % of the patients had lupus nephritis class IV on biopsy at the time of diagnosis.(6) 
Around 80 % of the patients have microscopic haematuria while macroscopic haematuria is 
rare in lupus nephritis and about half of the patients will have reduced GFR.(5) 
 Korbet et al in 2000 had reported that patient survival is about 95 % and renal survival 
is 94 % in those who achieve remission.(25) Both the patient as well as renal survival is a lot 
lower in the case of those who do not achieve remission.   
Diagnosis 
 The gold standard for the diagnosis of lupus nephritis is a renal biopsy. However, a lot 
of other test do aid in coming to diagnosis of lupus nephritis including 24 hour urine protein, 
serum creatinine, serum albumin, estimated GFR and urinalysis. The urinalysis report 
generally shows a nephritic picture with RBC casts, RBC’s and proteinuria. A rising Anti-
dsDNA as well as hypocomplementemia strongly points towards active lupus renal 
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disease.(5)Sircar et al had reported that around 78 % of the patients with lupus nephritis had a 
positive Anti-dsDNA.(6) 
Treatment 
The European League against Rheumatism (EULAR) recommends MPA as the first line of 
treatment along with corticosteroids in the treatment of higher stages (Stage III, IV and V) of 
lupus nephritis. They recommend a starting dose of 1 g/day given every 12 hours. The dose 
can go up to 3g/day depending upon the patient response.(9) There is a lot of interest in using 
biological agents like rituximab and belimumab for the treatment of SLE. In fact, a large 
study has not shown any added benefit of using rituximab for lupus nephritis. Other agents 
like rontalizumab and laquinimod are also late stage clinical trials for the treatment of 
SLE.(10) But still, the current mainstay of treatment happens to be Mycophenolate and 
steroids. 
Pharmacology of mycophenolate mofetil 
Mycophenolate mofetil (MMF) is the commercially available morpholinoethyl ester 
prodrug of the immunosuppressant mycophenolic acid. (MPA).(26) It is a reversible inhibitor 
of inosine monophosphate dehydrogenase (IMPDH) in purine biosynthesis. The T 
lymphocytes are heavily reliant upon the de novo pathway for the synthesis of purines. Other 
cells are able to recover purines via a separate, scavenger, pathway and are, thus, able to escape 
the effect.(27) Figure 2 shows the commonly used immunosuppressants and their site of action 
in the T cell activation pathway. MMF also block the B cell antibody production which is 
responsible for the reduced flares in SLE.(26) 
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Figure 2: Site of action of common immunosuppressive agents 
 
MPA is a fermentation product from various Penicillium species and was first 
isolated in 1898. However, its immunosuppressive properties were not discovered till the 
1970s.(28) 
The IUPAC name of MMF is 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-
7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate. It has a molecular mass of 
433.5 and it has an empirical formula of C23H31NO7. 
Figures 3 and 4 show the structure of MMF and MPA respectively. 
 
T cell activation Pathway
Antigen recognition
Cytokine Synthesis
Cytokine action
DNA synthesis, cell 
proliferation and cell division 
Site of action of common 
immunosuppressive drugs
Polyclonal and monoclonal 
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Figure 3: Structure of Mycophenolate Mofetil 
 
Figure 4: Structure of Mycophenolic acid 
 
Mycophenolate is available as two formulations- mofetil and as enteric coated 
formulation. The mofetil is directly converted to mycophenolic acid (MPA) and the enteric 
coated (mycophenolate sodium) is available as MPA. MMF has a bioavailability of >90%. 
After absorption the prodrug MMF is rapidly converted to MPA by plasma esterases. This 
conversion from MMF to the active form MPA is rapid in the blood, intestine, and liver, after 
gastrointestinal absorption.(29) MPA is then metabolized to MPAG (Glucuronide conjugate of 
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MPA) and to Acyl MPAG. MPA is one drug that undergoes extensive enterohepatic 
recirculation and thus often presents with two peaks due to reabsorption.(30) 
MPA, at clinically relevant concentrations, is 97% bound to plasma albumin. MPAG is 
82% bound to plasma albumin at concentration ranges normally seen in stable renal transplant 
patients; however, at higher MPAG concentrations (observed in patients with renal impairment 
or delayed renal graft function), the binding of MPA may be reduced as a result of competition 
between MPAG and MPA for protein binding.(31,32) 
MPA – use in transplant 
Mycophenolate Mofetil is being increasingly used for the prevention of renal allograft rejection 
due to its good efficacy and lesser toxicity compared to other immunosuppressants.(5,6) 
Dooley et al showed that patients on MPA had lesser side effects due to immunosuppression 
than azathioprine.(6) 
Therapeutic drug monitoring (TDM) of MPA in transplant 
TDM of MPA is now accepted in many parts of the world.  The reasons for TDM 
include the high (10 fold) inter individual variability in the pharmacokinetics of MPA.(12) It 
has also been observed that there is a very strong association between total MPA-AUC and 
acute rejection (p<0.001)(33). It is generally agreed that MPA dose should be titrated to keep 
the MPA-AUC (0-12 hrs.) within 30-60mg.hr/L to avoid rejection.(12–14) 
 
 
MPA- use in autoimmune disease (AID) & TDM of MPA in SLE 
The optimization of immune suppressive therapy is still a major concern in patients 
with SLE and other autoimmune diseases. The clinical application of TDM of MMF in 
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autoimmune disease is a topic of debate. In the past decade many different studies have been 
done to study the pharmacokinetics of mycophenolic acid in autoimmune diseases and 
especially in SLE, both in paediatric as well as adult patients.(12,35–39) 
Autoimmune diseases such as systemic lupus erythematosus (SLE) may present with a 
low serum albumin concentration which may alter the pharmacokinetics of MPA in such 
patients. It has also been found that elevated concentrations of MPAG (Glucuronide metabolite 
of MPA) will displace MPA from its binding site, thereby increasing the free concentration in 
plasma(40). 
It is generally accepted that TDM is required in lupus nephritis patients taking MPA 
also as advised by the EULAR but they did mention that the actual therapeutic range for MPA 
in lupus nephritis is still under investigation.(9) Djabarouti et al looked at the pharmacokinetics 
of MPA in SLE patients and concluded that there was large inter-patient variability in the MPA-
AUC thereby indicating that TDM may be necessary.(38) Other studies have also mentioned 
that MPA TDM in AID seems to be necessary and valuable in the optimization of 
immunosuppressive therapy for individuals.(12) However, although monitoring does occur in 
patients receiving MPA for autoimmune diseases there is scant literature on the therapeutic 
monitoring of MPA in patients with SLE. Woillard et al in 2014 have reported that in children 
with SLE having MPA AUC <45 mg.h/L are less prone to having relapses. (82 % v/s 52 %, 
p<0.01).(39) 
The current literature does not give any objective evidence to define the best strategy 
for TDM of MMF in patients with SLE. However, several studies in adult and children with 
SLE taking MMF have reported that the TDM of MMF based on measuring the AUC can be 
justified. It is obvious that both under as well as overexposure could have several unwanted 
consequences for patients on MMF for SLE. Very little information is available regarding the 
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exposure toxicity relationship of MMF but it seems quite clear that AUC >60 mg.h/L does not 
give any added benefit and might actually lead to a greater incidence of adverse drug 
reactions.(39) 
TDM of MPA vs. outcome in SLE 
Lertdumrongluk et al have shown a positive correlation between the MPA-PK and 
therapeutic responses in patients with SLE.(31) Djabarouti et al showed that the steady state 
mycophenolate mofetil concentrations are very useful in predicting clinical flares in systemic 
lupus erythematosus.(37) A recent study noted that maintaining a single MPA trough 
concentration above 2.5-3 mg/l was probably sufficient to prevent flares in SLE.(41) This 
suggests that MPA concentrations should be controlled in order to improve therapeutic 
efficacy. But however it is still uncertain as to whether a single concentration 12 hours post 
dose is enough for the TDM of MMF or the whole exposure as area under the curve needs to 
be monitored as is the practice for MMF use in transplant patients. De winter et al tried 
obtaining an equation using only the trough concentrations to predict the MPA AUC in patients 
taking MMF for autoimmune diseases using multiple regression analysis but they found that 
the equations had a high bias and imprecision and it only had a coefficient of determination of 
0.48.(42) 
Difference of TDM for MPA in transplant versus AID 
Neumann et al.(8, 10) compared the pharmacokinetics (PK) of MPA (MMF and Enteric 
Coated-MPA) in renal transplant (RTX) patients and patients with autoimmune diseases.  They 
found significant differences between the PK of the two groups. In AID patients, the MPA 
concentrations were found to be higher than in the renal transplant group. In AID, the MPA-
PK was less affected by renal function as compared to RTX patients. Discuss the results of 
their study. Neumann et al found, on comparing the kinetics between kidney transplant and 
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AID patients, that the data could not be extrapolated from one to the other suggesting the need 
for more studies in MPA pharmacokinetics in SLE. (12) 
Importance of free drug monitoring and free fraction 
Hypoalbuminaemia plays a major role in the concentration of drugs which have a very 
high plasma protein binding.(16) In such cases, it is the free (pharmacologically active) drug 
concentration and not the total drug concentration that is important.(16,17) This can lead to the 
patient’s dose being increased which may in turn lead to toxicity. (43) A few studies have 
previously reported that the free fraction of MPA may be more clinically relevant as compared 
to Total MPA concentrations in blood. Mino et al also postulated that the serum albumin 
concentrations might be very useful in predicting the free MPA concentrations in plasma.(40) 
In a study done in children, it was postulated that when the albumin levels were lower than 3.0 
g/dl, it was seen that the unbound (free) fraction of the drug increases thus, making more MPA 
available for metabolism and elimination.(39) 
Use of saliva as a biomatrix in TDM- its advantages 
Oral fluid for drug testing is easy to collect and non-invasive.(18)  Saliva is an 
ultrafiltrate and can be a viable alternative for the measurement of free drug in the central 
circulatory system.  The last decade has focused on target drugs and their pharmacokinetics in 
oral fluids.(18,44) There has been significant progress in the testing for drugs of abuse in oral 
fluids but little data is available for therapeutic drugs. A previous study comparing saliva MPA 
to free and total MPA in serum done in Caucasian renal transplant patients noted that with 
exception to the morning trough sample , there was a good correlation between the saliva MPA 
and both free MPA (r= 0.92) and Total MPA concentrations (r= 0.90).(45) They attributed the 
higher concentration in the saliva morning trough sample to the presence of blood (following 
teeth brushing and flossing) in the morning saliva sample. 
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 To our knowledge, no studies have been performed in Indians with lupus nephritis to 
correlate the saliva MPA concentrations to the total and free MPA concentrations in the plasma.  
 
Pharmacokinetic data analysis: 
 A few softwares are available for the elucidation of pharmacokinetic parameters using 
non-linear mixed effects modelling like Nonmem and Pmetrics(46) package for R(47), both 
of which use the computer language FORTRAN for their calculations. In this study, we used 
Pmetrics for R which was created after 3 decades worth of research and development at 
University of Southern California, Los Angeles, USA. This program uses either Iterative 2 
stage Bayesian (IT2B) or Non-Parametric Adaptive Grid (NPAG) algorithms to accurately 
detect the true dispersions of the data. Since many of the immunosuppressive drugs including 
MMF have a significant amount of enterohepatic recirculation, it has a bimodal distribution 
of Kel. The authors mention that they found the NPAG algorithm to be superior to IT2B runs 
in detecting the bimodal distributions of the Kel (elimination rate constant) of 
pharmacokinetic data.(46) The major disadvantage of using this package for R is that the user 
has to be proficient in R. An added advantage of Pmetrics is its ability to generate a lot of 
custom generated plots apart from the standard Pmetrics functions and this is an advantage 
over softwares like Nonmem.(46) 
Limited Sampling strategies (LSS) for mycophenolate in autoimmune diseases 
 AUC is the best measure to characterize the drug exposure. However, to get a full 
profile, it requires collection of many blood samples (often more than 8) and it also requires 
the patient to be in the hospital/laboratory during the whole duration of sampling. Although 
trough concentrations have been used to indicate drug exposure for other drugs, for MPA, it 
does not correlate well with both AUC as well as treatment outcomes.(15) 
35 
 
Therefore, there arises a need to develop a robust equation to predict the AUC using the least 
number of samples and also taking into account the amount of time the patient has to spend in 
the hospital/lab. The benefits of LSS’s include reduced cost, greater turnaround time, better 
allocation of resources and potentially shorter hospital stay for patients. A LSS established 
for a particular patient group need not be applicable in patients with a different disease even 
though the same drug is being used for that disease as well. There have been a few LSS 
developed for MPA in AID.(15) The best predictors for MMF AUC included 3 samples, 
taken pre-dose and at 1 and 3 hours post dose. However, majority of the LSS developed by 
using multiple regression analysis are plagued by a high bias and imprecision of 0.8 and 22.6 
%.(15)  In this study, we wanted to look into the possibility of developing and validating a 
LSS to estimate MPA AUC0-12, having an acceptable bias and precision, to be used in 
patients with lupus nephritis.  
There are two different ways to derive a limited sampling strategy for any drug i.e., 
multiple regression analysis (MRA) or Bayesian a posteriori analysis.(48–50) In the case of 
MRA, a stepwise linear regression is performed to determine the relationship between the 
dependant variable (usually AUC) and the independent variables (the concentrations of the 
drug at various time points). The relationship is described as a function in the form of:(48–
50) 
AUCn= A + A0C0 + A1C1 +………..+ AnCn 
 Where AUCn is the Area under the curve of the drug to time n; A is a constant (y-
intercept); A0, A1, An are fitted constants and C0, C1, Cn are the concentrations at various time 
points. Using MRA for the analysis has its own advantages and limitations.(50) Advantages 
include: No prior knowledge of the pharmacokinetics is required; needs only a simple 
statistical procedure which can be done on most statistical softwares and once the equation is 
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finalized, the AUC can be calculated very easily and can even be done manually and lastly, it 
can be used in a routine clinical setting without extensive training of the staff. Its 
disadvantages include: timing of the sample is critical and it only works for patients on that 
particular dosage form for a particular disease/condition. Equations with a high r2 (coefficient 
of determination) values are generally the most ideal candidates for the LSS. Bayesian 
analysis on the other hand uses a mix of the population predictions as well as the individual 
predictions for AUC.(50) The prediction of parameters using the Bayesian function is as 
follows: 
        	         = 
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Here, Ppop is the population average of the parameter. P1 is the individual average of 
the parameter P. Similarly, Cobs and C1 are the observed and predicted concentration values 
respectively. Var(P) and var(C) are the variances of the estimated parameter and the predicted 
concentrations respectively.(50) 
The biggest advantage of bayesian over MRA is that the samples can be collected at 
any time point in the AUC, i.e., precise sampling points are not required and it gives greater 
flexibility in a clinical setting. Apart from that, other advantages include the fact that other 
covariates such as age, sex, weight etc. can be put into the model. However, it is not without 
any disadvantages.(50) It is a complex algorithm and it needs trained staff. Also, there needs 
to be a specific PK model for the drug and thus intricate knowledge of the drug’s PK is 
required for analysis and interpretation.  
Another important part of both Bayesian and MRA is that the models need to be 
validated. In the ideal setting,  when the sample size is adequate, the patient population is  
divided into two groups, an index set to develop the LSS and a different validation set (to 
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validate the LSS). However with a small sample, an alternative to this is the development of 
LSS using all the patients’ pharmacokinetic data and then using a bootstrap model to validate 
the equation. A bootstrap like validation has been performed previously to validate a LSS 
model in cyclosporine.(51) Validation entails the calculation of bias (measured as prediction 
error) and imprecision (which can be measured by using either the absolute prediction error 
or the root mean square prediction error). It is generally accepted that the imprecision be <15-
20 % so as to not make a difference clinically.(50) 
High Performance Liquid Chromatography (HPLC) 
 HPLC is a technique used for the separation of components in a mixture, 
identification as well as quantification of each component. It can be used for the separation of 
organic molecules as well as ions. HPLC requires two phases: a solid stationary phase which 
is usually packed in a stainless steel column and a liquid mobile phase. HPLC can be used to 
determine the amount of pharmaceutical substance present in a particular solution. The HPLC 
instrument consists of a pumping system, injector, chromatographic column, stationary and 
mobile phases, oven, detector and a data collection device like a computer. The figure below 
(figure 5) shows the HPLC instrument used for analysis in our Clinical Pharmacology Unit. 
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Figure 5: HPLC machine used for this study 
 
Legend: 
1 – Central Console 
2 – Sample Tray 
3 – Mobile Phase 
4 – Chromatographic column containing the solid phase housed in the oven. 
5 – UV-Vis Detector 
 The figure below (figure 6) gives the schematic representation of the HPLC 
apparatus. 
3 
1 
2 
4 
5 
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Figure 6: Schematic representation of the HPLC apparatus: "HPLC apparatus" by WYassineMrabetTalk✉ 
This vector image was created with Inkscape. - Own work. Legend based on: Practical High-performance 
Liquid Chromatography by Veronika Meyer, 4th edition, John Wiley 
 
Schematic representation of an HPLC unit. (1) Solvent reservoirs, (2) Solvent degasser, (3) Gradient 
valve, (4) Mixing vessel for delivery of the mobile phase, (5) High-pressure pump, (6) Switching 
valve in "inject position", (6') Switching valve in "load position", (7) Sample injection loop, (8) Pre-
column (guard column), (9) Analytical column, (10) Detector (i.e. IR, UV), (11) Data acquisition, 
(12) Waste or fraction collector. 
Types of HPLC 
The main types of HPLC are: 
1) Normal Phase Chromatography 
2) Partition Chromatography 
3) Displacement Chromatography 
4) Reversed Phase Chromatography (RP-HPLC) 
5) Ion Exchange Chromatography 
 All these different types of HPLC have been developed keeping in mind their usage in 
separation of different organic substances. The most commonly used variety for separation 
and quantification of therapeutic agents is the RP-HPLC. RP-HPLC requires a non-polar 
stationary phase and an aqueous polar phase. Stationary phase is usually made up of silica. In 
RP-HPLC, polar substances elute faster and have a shorter retention time (time taken for the 
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substance to elute out of the chromatographic column and be detected after starting the 
injection). RP-HPLC operates on the principle of hydrophobic interactions between the 
analyte of interest and the stationary and mobile phases.(52) It is important to add a buffering 
agent to the mobile phase as the mobile phase pH can be an important factor in deciding the 
retention time of the analyte of interest.   
Detectors 
The most common detectors employed in the HPLC for measuring therapeutic agents 
are UV-Vis (Ultraviolet and visual spectrum detector) and the MS (Mass spectrometer) 
detectors. HPLC machines with MS detectors are costlier than those with UV-Vis detectors. 
Mobile Phases 
 The most common mobile phases that are used for separation are Acetonitrile (ACN) 
and Methanol combined with water (or buffers). Other acids like trifluoroacetic acid, formic 
or phosphoric acid may be added along with the above depending upon the use. The 
composition of the mobile phase may be kept constant (Isocratic flow) or varied (Gradient 
flow) throughout the analysis.  
 
JUSTIFICATION FOR THE STUDY: 
Initially, in patients with AID, MMF doses of up to 2 g daily were used.(43) It is 
questionable whether standard dose therapy is the best way to treat a patient as dose is not a 
good  predictor for MPA exposure and there is a  large inter-individual variability in 
pharmacokinetics of MPA.(40,53) Since patients with autoimmune diseases are regularly 
treated with only one or two immunosuppressive drugs, an adequate MPA exposure may be 
even more important compared to renal transplant recipients receiving multiple 
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immunosuppressive drugs. Limited pharmacokinetics of MMF has been carried out in patients 
with autoimmune disease. (31,40,54) 
In India, there is a higher incidence of patients having low albumin, especially among 
those with AID. Presently dose adjustments of mycophenolate in our centre is based on total 
MPA AUC0-12. Patients with a poor renal function (creatinine clearance <25 mL/min) and 
patients with low albumin (<32 g/L) are known to have a lower interdose MPA AUC(16). 
Hypoalbuminaemia as well as renal insufficiency, results in a higher free fraction of MPA 
which may result in a higher MPA clearance(16).Therefore caution should be used in 
interpreting total MPA concentrations in patients with severe renal impairment or 
hypoalbuminaemia.  
 The objective of the thesis was to study the exposure of mycophenolate (AUC0-12) in 
SLE patients and to describe the pharmacokinetic parameters of mycophenolic acid in these 
patients. The other objective was to develop and validate limited sampling strategy equations 
to predict MPA AUC0-12. Is it possible to measure free MPA concentration by HPLC? 
Measurement of free MPA is expensive because of the requirement of the ultrafiltrate which is 
obtained using centrifugal filters. In resource limited settings, can a simple non-invasive saliva 
specimen or total MPA measurement (which is done as patient care in this centre) be used to 
estimate free MPA concentration, in both normal and hypoalbuminaemic patients. 
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Methods 
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Patient Population 
This was an open label prospective 2 year study conducted in the Clinical Pharmacology 
Unit, (Department of Pharmacology and Clinical Pharmacology) Christian Medical College 
(CMC), Vellore. Patients were recruited from Department of Nephrology, CMC, Vellore.  
The study was approved by the Institutional Review board. Patients were recruited after the 
informed consent was obtained. All patients recruited were diagnosed with Systemic Lupus 
Erythematosus (SLE) with varying degrees of Lupus Nephritis. They were prescribed MMF 
as Mycept® (Panacea Biotec Ltd) twice daily and dose was based on the clinician’s 
discretion. All the patients had received MMF for at least 5 days before samples were 
collected. The timing and compliance of MMF was confirmed prior to including them in the 
study. Only patients who had been taking mycophenolate, twice daily, regularly and were 
taking the doses at 8.00/9.00am and 8.00/9.00 pm were considered eligible to be included in 
the study.   The following demographic, anthropometric and laboratory parameters were 
noted on the day of the study; age, sex, weight, haemoglobin, albumin, total and differential 
blood counts, blood urea, serum creatinine and GFR. 
Inclusion criteria: - 
 Patients diagnosed with lupus nephritis   
 Patient should have been on mycophenolate for a minimum of 5 days. (to attain 
steady state in terms of mycophenolate pharmacokinetics)  
 Patient should be willing to be in the Clinical Pharmacology Unit for 12 hours. 
 Age>18 years 
Exclusion Criteria: - 
 Patients on enteric coated mycophenolate sodium and other MMF brands (except 
Mycept)  
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 Post renal transplant patients. 
 Pregnant women  
 Critically ill patients  
 
Blood and saliva sampling 
The patient presented to the Clinical Pharmacology Unit at 8.00 am, after an overnight fast. 
An insyte was inserted into a forearm vein.  A blood specimen for the measurement of MPA 
plasma trough concentration was taken, after which MMF was administered orally. 
Additional serial blood specimens (4ml) were collected into EDTA tubes after 0.5, 1, 1.5, 2, 
2.5, 3, 4, 6, 8, 12 hours post-dose. Food was permitted only two hours after MMF was 
administered. Specimens were immediately centrifuged and the plasma separated into clean 
eppendorfs and analysed immediately or stored at -20 degrees till analysis the following day.  
 In addition, the 1 hour plasma specimen was stored at -20˚ C and was used to measure the 
free MPA concentration .At the time of analysis of free MPA concentration, 500 µl of plasma 
was added into the centrifugal filter units (Amicon Ultracentrifugal Filters) and centrifuged at 
13,000 rpm for 25 minutes.  
After the 1 hr blood sample was collected, the patient was given a dispensable container for 
collection of saliva. Unstimulated saliva specimen was collected and the specimen was 
analysed immediately or stored at -20˚ C till analysis.  
Chemicals and reagents used 
Acetonitrile (ACN), Methanol and acetic acid were purchased from Sigma-Aldrich. 
Mycophenolic acid and Carbamazepine (CBZ) (internal standard- IS) pure powders were also 
purchased from Sigma-Aldrich. Amicon Ultracel® YM-30 [0.5 ml 30kDa (kilo Dalton)] 
centrifugal filter units were purchased from Merck Millipore (Millipore, Cork, Ireland). The 
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extraction process for saliva MPA required solid phase extraction (SPE) cartridges purchased 
from Phenomenex (Strata-X®). 
20 mM Phosphate buffer solution was prepared, at pH 3.5. It was prepared by mixing 1.7418 
g of dipotassium hydrogen phosphate (K2HPO4) in 500 ml of Millipore water and 1.3609 g of 
potassium dihydrogen phosphate (KH2PO4) in 500 ml of Millipore water. These were then 
mixed together and the pH was adjusted to 3.5 using orthophosphoric acid.  All the 
pharmacokinetic measurements were done using a Waters Alliance e2695 separation module 
with detection in Waters 2489 UV-Visual detector (Waters, Milford, MA, USA).  
Preparation of stocks and calibrators for free and saliva MPA 
 For both Saliva and free MPA detection, a Quality Control (QC) stock (0.01 µg/µl) 
and two Standard stocks (0.01 µg/µl & 1 µg/ml) were separately prepared in saliva for saliva 
MPA and saline for free MPA. The reason for the stocks not being prepared in plasma for 
free MPA was because the patient sample had to pass through a biological membrane filter 
and were devoid of any proteins and other products which could have interfered with the 
MPA retention time for the assay. 
For both free and saliva MPA detection, 2 ml of the standards (Std.) were prepared as 
follows: 
Std. 1 µg/ml: 200 µl of stock 0.01 µg/µl + 1800 µl of saliva/ saline 
Std. 0.5 µg/ml: 100 µl of stock 0.01 µg/µl + 1900 µl of saliva/ saline 
Std. 0.25 µg/ml: 50 µl of stock 0.01 µg/µl + 1950 µl of saliva/ saline 
Std. 0.05 µg/ml: 100 µl of stock 1 µg/ml + 1900 µl of saliva/ saline  
Std. 0.025 µg/ml: 50 µl of stock 1 µg/ml + 1950 µl of saline (For free MPA detection only) 
Std. 0.010 µg/ml: 20 µl of stock 1 µg/ml + 1980 µl of saliva/ saline   
46 
 
Sample preparation 
 Four ml blood was collected and immediately centrifuged (at 3000 rpm for 5 minutes) 
to separate out the plasma, for measurement of total MPA concentration. It was analysed 
immediately or plasma was stored at -20˚C till analysis. For analysis of free MPA 
concentrations, at the time of analysis, 500 µl plasma was passed through the Amicon 
Ultracel® centrifugal filters. The plasma was filtered at 13000 rpm for 25 min and it yielded 
about 150-200 µl of ultrafiltrate. This ultrafiltrate was used for estimation of free MPA 
concentration.  
Extraction procedure 
The extraction procedure for free MPA, saliva MPA and total MPA are given in figure 7, 8 
and 9 respectively. The extraction of saliva MPA required a solid phase extraction unlike 
others.  
47 
 
Figure 7: Extraction process for MPA in Saliva at 1 Hr  
 
  
Figure 8: Extraction procedure for Free MPA at 1 Hr 
 
1 ml Methanol + 1 ml Water+ 40 µl of Internal standard (IS) [ 
20µg/ml of CBZ] + 500 µl of saliva
Vortex for 30 sec and add 1 ml of 2 % Acetic acid
Elute (pass through solid phase extraction cartridges) with 1 ml ACN
Blow down under Nitrogen gas at 37˚ C
Reconstitute with 100 µl of mobile phase
Inject 30 µl into the HPLC
20 µl of Internal standard (IS) [ 10µg/ml of CBZ] + 150 µl of 
supernatant after passing through Amicon centrifugal filter
Vortex for 30 sec
Inject 80 µl of supernatant into the HPLC
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Figure 9: Extraction procedure for total MPA in plasma 
 
 The HPLC conditions for total, free and saliva MPA are listed below:  
Column: Discovery HS C18 column 5 µm pore size (250 X 4.6mm) 
Mobile Phase 
For total MPA: 
           Type of flow: Isocratic, at 1.2 ml/min 
           49 % - 20 mM Phosphate buffer at pH 3.5 
           51 % - Acetonitrile 
For free MPA and for saliva MPA:  
           Type of flow: Isocratic, at 1.2 ml/min 
           54 % - 20 mM Phosphate buffer at pH 3.5 
           46 % - Acetonitrile  
40 µl of Working stock of IS (CBZ) + 300 µl of plasma
Vortex for 30 sec
Add 400 µl of ACN and vortex for 30 seconds
Centrifuge (13000 rpm for 8 min) and separate supernatant into a clean eppendorf
Inject 20 µl of supernatant into the HPLC
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Detection Wavelength for total, free and saliva MPA – 215 nm 
Injection volume: 
Total MPA – 20 µl 
Free MPA- 80 µl 
Saliva MPA- 30 µl 
Retention time 
For free MPA, Drug at 7.37 and IS at 4.84 minutes 
For saliva MPA, Drug at 7.92 and IS at 4.84 minutes 
For total MPA, Drug at 5.80 and IS at 4.32 minutes 
 
Assay Validation for free and saliva MPA 
 The assay for total MPA concentrations is already validated and the assays method 
has been detailed in a previous paper from our centre.(55) 
The steps for validation of an assay should include the following steps (from Bioanalytical 
method validation, US FDA 2013): 
1) Selectivity 
 Lower limit of Quantification (LLOQ) is defined as the lowest concentration at which 
there is a precision of at least 20 % and an accuracy of at least 80 %), Selectivity would 
include no interference when tested with blank samples (no internal standard or analyte), 
patient blank samples (samples from similar cohort of patients who are not on the analyte or 
the internal standard), zero standard samples (extract with internal standard but not having 
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analyte). Patient samples which should have both the analyte as well as the internal standard 
are also assayed to rule out interference. 
2) Linearity 
 A calibration curve is documented to check the linearity from the lowest standard to 
the highest standard.  The calibration needs to be performed in the same matrix as intended in 
the future analysis. At least five to six concentrations are used to cover the expected range. 
3) Accuracy and Precision (Reproducibility) 
 Accuracy is a measure of the closeness of the results obtained by the procedure to the 
true value. Precision is defined as the degree of agreement among individual test results 
obtained when the method is applied to a multiple sampling of a homogenous sample. 
%	   =
  
    
	× 100 
 Here, CV refers to coefficient of variation (relative standard deviation). SD refers to 
the standard deviation.  
For accuracy and precision tests, the samples are prepared on the same day from the same 
batch (multiple injections made from a single extracted sample) to test for variations in the 
detection by HPLC at different points during the day.  
Also from the same sample, five different extractions are injected to check for variability 
between different extractions. The results are expressed in Mean, SD, % CV and accuracy.   
Accuracy and precision were also checked to measure inter-day variation with the same 
samples being tested with a gap of at least 3 days. 
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Free MPA 
The LLOQ for free MPA in our assay was found to be 0.01 µg/ml. Quality control (QC) 
samples were prepared from a separate batch at a concentration of 0.1 µg/ml.  
For intraday variation, each sample of the patient plasma sample and QC 0.1 µg/ml was 
measured at 5 different times during a single day. The coefficient of variation (CV) for the 
intraday validation was calculated. The inter-day variation was determined by analysing the 
patient plasma sample on two different days, six days apart and the CV was calculated. 
 The calibration curve after the filtration of the solutions was set at 0.010, 0.025, 0.050, 
0.250, 0.500 and 1.0 µg/ml. The curve was considered to be linear when the coefficient of 
determination r2≥ 0.995.The curve linearity was maintained between 0.10 and 1.0 µg/ml. 
Saliva MPA  
Saliva blanks were obtained from patients who were not on any dosage form of MPA. The 
LLOQ for free MPA in our assay was found to be 0.01 µg/ml. Quality control (QC) samples 
were prepared from a separate batch at a concentration of 0.1 µg/ml.  
For intraday variation, the QC 0.05 µg/ml was measured at 5 different times during a single 
day. The coefficient of variation (CV) for the intraday validation was calculated.  
Apart from this, variations in six different extractions of the QC 0.05µg/ml was also done and 
the CV was calculated. 
 The calibration curve after the filtration of the solutions was set at 0.010, 0.050, 0.250, 0.500 
and 1.0 µg/ml. The curve was considered to be linear when the coefficient of determination 
r2≥ 0.995. The curve linearity was maintained between 0.010 and 1.0 µg/ml.  
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Flowchart of the sequence of events: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient with Lupus nephritis and on Mycept 
preparation of MMF 
Sent to the Clinical Pharmacology Unit (Clin Pharm) 
visit) 
 Discontinue 
YES 
Blood specimens at Trough, 
0.5,1,1.5,2,2.5,3,4,6,8,12 hrs 
after  mycophenolate dose 
Written informed consent 
Saliva specimen collection at 1.0 
hr 
 Analysis of Total MPA 
AUC 
 
 Analysis of Free MPA conc. at 1.0 hr 
 
 Analysis of Saliva MPA Conc. at 1.0 hr 
Patient reports to Clin Pharm. Unit and insyte is put and test started by 8.00 am 
Low albumin Normal albumin 
Albumin level checked 
NO 
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Sample Size 
               The sample size was calculated to be 30 based upon the following: 
Detection of a significant correlation of 0.5 between the saliva MPA and free MPA in plasma 
at 1 hour, 
Power 80% & 
Level of Significance 5% 
 
Pharmacokinetic and Statistical Analysis 
Calculation of MPA AUC0-12 hr 
 The trapezoidal rule is an accurate estimate of the area under the concentration-time 
curve. It breaks down the area to be measured into small trapezoids to calculate AUC. Its 
calculation is depicted in the figure below. 
Figure 10: Calculation of AUC using trapezoidal rule 
 
The equation for calculating AUC is as follows: 
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Here, C1 and C2 are concentrations at time points t1 and t2 respectively. 
Therefore, AUC0-12 hr is calculated as  
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Here, Ct refers to the concentration of the drug at time t. 
Development and validation of LSS 
All statistical analysis were performed using R (version 3.1.5). Pharmacokinetic parameters 
were obtained by using Pmetrics (Version 1.2.6) package for R. Overall, 30 twelve hour 
pharmacokinetic profiles were obtained. The limited sampling strategy (LSS) development 
was similar to a paper published from our Clinical Pharmacology Unit.(56) Stepwise multiple 
linear regression was performed using MPA AUC 0-12 hr as the independent variable and the 
total MPA concentrations in plasma at 0, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hr as the dependant 
variable. The MPA AUC 0-12 hr was first checked for normality using Kolmogrov Smirnov 
test.  
                        The equation derived after running the regression was in the form of AUC0-12= 
A+ A0C0+ A1C1 +………..+ AnCn, where A, A0, An are fitted constants which are associated 
with the concentrations at 0, 1 and n hours post dose. The prediction bias of these estimates 
derived by the LSS was calculated by measuring the Prediction error and the absolute 
prediction error by the following formulae: 
  %	 = 	100 ×
(   	    −      	        	   )
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The absolute prediction had to be <15% for it to be clinically acceptable. 
 Then bootstrap validation (n=1000) was performed for the regression equation using 
R. The new LSS equation was used to calculate the estimated MPA AUC0-12 hr. The 
prediction bias as well as the absolute precision error (expressed as a percentage) were 
calculated along with their respective 95 % confidence intervals (CI). For assessing the 
agreement between the Observed MPA AUC0-12 hr v/s the LSS estimated MPA AUC0-12 hr, the 
Bland Altman method (Mean v/s Difference Plot) was used as described previously.(57) 
Intraclass correlation coefficient (ICC) shall be used to compare between the LSS estimated 
and the actual observed MPA AUC0-12 hr. 
               Pharmacokinetic variables like Ka (absorption rate constant), Ke (Elimination rate 
constant), Vd (Volume of Distribution) and Cl (clearance) were estimated using non 
parametric adaptive grid function in Pmetrics package for R. The Pmetrics Package requires a 
model file to be supplied (in FORTRAN syntax) along with the data file as it uses the 
computer language FORTRAN do all the calculations. As our study protocol did not involve 
measurement of the bioavailability of the Mycept® tablets, bioavailability was arbitrarily set 
to 60- 95 % based upon previous reports of bioavailability of MMF. 
Correlation between Free v/s total MPA &Saliva v/s free MPA 
For the correlation between saliva MPA and free MPA in plasma, Spearman correlation was 
performed, both before and after dividing the data based upon low and normal serum 
concentrations. Also stepwise multiple regression was performed similar to that used in the 
LSS determination to see if saliva MPA or total MPA in the plasma can be used to predict the 
free MPA concentrations in the plasma.  
56 
 
 
 
57 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
Bioanalytical validation of assay for free MPA –HPLC 
Selectivity 
The figure (figure 11) below shows the chromatogram of two normal blank samples (plasma 
sample of a person who is not on MMF (drug) or CBZ (IS)) compared to a standard 
chromatogram for free MPA. 15 such blanks were run to confirm that there were no 
extraneous peaks that could interfere with the drug or the IS peak.  This confirmed that 
plasma samples from patients not on mycophenolate did not have any peaks that interfered 
with the MPA or IS drug peaks. 
10 samples were also run containing only the IS and no drug (zero standards). This was done 
to confirm there was no interference from the internal standard at the retention time of the 
drug 
Apart from this, samples were assayed from 5 patients on MMF, to confirm the drug peak 
and the drug retention time.  
To conclude, this assay is selective for free MPA and there was no interference at the 
retention time for both, MPA and CBZ. 
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Figure 11: Chromatogram of standard 1 with two patient blanks 
 
Calibration Curve - To Confirm Linearity 
The chromatogram of the standard curve for free MPA is given in the figure below (figure 
12). A standard curve was run to test the linearity. The results are tabulated in table 2 below. 
Figure 12: Chromatogram of a standard curve for free MPA
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Table 1: Standard curve for free MPA (using loop size of 80ul) 
STANDARDS INTERNAL STANDARD DRUG RATIO 
µg/ml RT Area RT Area  
1 4.799 126420 7.370 84504 0.67 
0.5 4.796 99311 7.370 43772 0.44 
0.25 4.786 120414 7.370 20903 0.17 
0.05 4.796 121174 7.389 4161 0.03 
0.025 4.797 122664 7.392 2127 0.02 
0.01 4.800 104705 7.404 956 0.009 
QC(0.1) 4.788 124007 7.401 9299 0.07 
 RT: Retention time  
 In the above table and other tables to follow in this section, RT refers to the retention 
time (time elapsed since start of the analysis to the time of detection in minutes). Area in the 
table refers to the area of the peak in the chromatogram of the analysis. IS refers to the 
internal standard Carbamazepine (CBZ).  
The calculated linearity was in the form of an equation for a straight line: 
"  =    +  ”; Where m is the slope and c is the intercept. From the above table, the slope 
was 0.669, the intercept was 0.0012 and the correlation was 0.999. The calculated QC was 
0.103 µg/ml.  
To conclude the curve was linear from 0.01 µg/ml to 1 µg/ml. The calibration curve for free 
MPA in plasma is given in the figure below (figure 13): 
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Figure 13: Calibration curve for free MPA in plasma 
 
Test of Accuracy and Precision (Done using 20 µl Loop) 
Reproducibility of the assay was tested by re-injecting from same extraction of 0.1 
µg/ml spiked sample. The sample from the same batch with the same extraction was injected 
six times on the same day. The reproducibility of the assay was actually tested using the loop 
volume of 20 µl but the assay was later run using a loop volume of 80 µl. Considering that 
the conditions remained the same except the loop volume, we expected the assay to improve 
without having any effect on reproducibility. 
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Table 2: Intra-day variation with same extraction, spiked sample (0.1µg/ml) 
 INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.782 60105 7.152 1956 0.03 0.0781 
2 4.859 60690 7.321 2435 0.04 0.1094 
3 4.871 57985 7.315 1924 0.03 0.0781 
4 4.858 61135 7.278 2058 0.03 0.0781 
5 4.858 62886 7.238 1771 0.03 0.0781 
6 4.823 59769 7.176 1969 0.03 0.0781 
 
Mean Concentration (sd) = 0.0833(.013) 
Accuracy= -0.016 
Coefficient of variation% = 15.33 % 
Reproducibility (reinjection) was also tested in a patient sample to check precision. Six 
different injections were run from the same sample and the same extraction at different times 
on the same day. The accuracy for this sample however cannot be calculated as it is not 
possible to ascertain the actual concentration of free MPA in this plasma sample. 
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Table 3: Intraday variation with same extraction for patient plasma sample  
 INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.782 56620 7.075 813 0.01 0.016 
2 4.796 47016 7.146 618 0.01 0.016 
3 4.794 56561 7.155 759 0.01 0.016 
4 4.801 56444 7.153 637 0.01 0.016 
5 4.803 59119 7.177 619 0.01 0.016 
6 4.827 56730 7.250 798 0.01 0.016 
Mean Concentration (sd) = 0.016(0)  
Coefficient of variation% = 0 % 
 Another method to check reproducibility includes variations with different 
extractions. QC (0.25 µg/ml) from the same batch was extracted at 6 different times during 
the day and injected to determine the variability between different extractions. 
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Table 4: Variations with different extractions of 0.25 µg/ml 
 INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.770 55036 7.119 4999 0.09 0.2656 
2 4.865 70103 7.268 5891 0.08 0.2344 
3 4.837 59269 7.186 5110 0.09 0.2656 
4 4.815 49151 7.160 5028 0.10 0.2969 
5 4.816 50785 7.171 5124 0.10 0.2969 
6 4.809 64192 7.174 5026 0.08 0.2344 
 
Mean Concentration (sd) = 0.2656(.028) 
Coefficient of variation % = 10.52 % 
Inter-day Accuracy and Precision  
The results of the inter-day variations are tabulated in table 6 below. Index number 1, 
2 and 3 represent Day 1 and 4, 5 was performed 6 days later.  
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Table 5: Inter-day variation Patient Plasma Sample 
 INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.801 56444 7.153 637 0.01 0.016 
2 4.803 59119 7.177 619 0.01 0.016 
3 4.827 56730 7.250 798 0.01 0.016 
4 4.782 56631 7.179 809 0.01 0.016 
5 4.794 54908 7.134 785 0.01 0.020 
 
Average Concentration (sd) = 0.0168(0.0018) 
Coefficient of variation% = 10.65 % 
To conclude, the assay developed for free MPA in plasma had good reproducibility, 
linearity and specificity and can be used to measure free MPA concentrations in the plasma. 
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Bioanalytical validation of assay for MPA in saliva –HPLC 
Selectivity 
The figure (figure 14) below shows the chromatogram of two normal blank samples (plasma 
sample of a person who is not on MMF (drug) or CBZ (IS)) compared to a standard 
chromatogram for free MPA. 10 such blanks were run to confirm that there were no 
extraneous peaks that could interfere with the drug or the IS peak.  This confirmed that 
plasma samples from patients not on mycophenolate did not have any peaks that interfered 
with the MPA or IS drug peaks. 
10 samples were also run containing only the IS and no drug (zero standards). This was done 
to confirm there was no interference from the internal standard at the retention time of the 
drug 
Apart from this, samples were assayed from 5 patients on MMF, to confirm the drug peak 
and the drug retention time.  
To conclude, this assay is selective for free MPA and there was no interference at the 
retention time for both, MPA and CBZ. 
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Figure 14: Chromatogram of a standard curve for MPA in Saliva 
 
 A standard curve along with the QC (Quality control) was run to check for linearity 
(table 7). 
Table 6: Standard curve for standards and QC of MPA in saliva  
STANDARDS INTERNAL STANDARD DRUG RATIO 
µg/ml RT Area RT Area  
1 4.630 1723422 7.233 923567 0.55 
0.5 4.623 1699040 7.217 422002 0.25 
0.25 4.629 1331401 7.238 171331 0.13 
0.05 4.636 1587166 7.247 37158 0.02 
0.01 4.625 1563236 7.214 9521 0.006 
QC(0.1) 4.619 1418657 7.219 64476 0.05 
 RT: Retention time  
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 The calculated linearity was in the form of an equation for a straight line as mentioned 
in the results section earlier. 
 From the above table, the slope was 0.505, the intercept was -0.00083 and the 
correlation was 0.999. The calculated QC was 0.103 µg/ml. The figure (figure 11) below 
shows the calibration curve for MPA in saliva. 
Figure 15: Calibration curve for MPA in saliva 
 
 
Test of Accuracy and Precision 
Reproducibility of the assay was tested by re-injecting from same extraction of 0.05 
µg/ml spiked sample. The sample from the same batch with the same extraction was injected 
six times on the same day (Table 8). 
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Table 7: Intra-day variation with same extraction QC (0.05 µg/ml) 
RUNS INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.836 1398302 7.912 46033 0.03 0.046 
2 4.850 1422944 7.930 48919 0.03 0.046 
3 4.838 1406414 7.920 45473 0.03 0.046 
4 4.854 1171252 7.937 36288 0.03 0.046 
5 4.843 1390257 7.922 46405 0.03 0.046 
6 4.853 1349174 7.938 44419 0.03 0.046 
 
Average Concentration (sd) = 0.046 (0) 
Inaccuracy= 8 % 
Coefficient of variation = 0 % 
 Another method to check reproducibility includes variations with different 
extractions. QC (0.05 µg/ml) from the same batch was extracted at 6 different times during 
the day and injected to determine the variability between different extractions. The results are 
tabulated in table 9 below. 
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Table 8: Variations with different extractions of QC (0.05 µg/ml) 
RUNS INTERNAL 
STANDARD 
DRUG RATIO CONCENTRATION 
 RT Area RT Area   
1 4.838 1406414 7.92 45473 0.03 0.046 
2 4.843 1390257 7.922 46405 0.03 0.046 
3 4.837 1335171 7.909 55120 0.04 0.059 
4 4.840 1429019 7.918 49750 0.03 0.046 
5 4.847 1490658 7.932 50079 0.03 0.046 
6 4.836 1398302 7.912 46033 0.03 0.046 
 
Average Concentration (sd) = 0.0482 (0.0053) 
Inaccuracy= 3.67% 
Coefficient of variation = 11.02 % 
To conclude, the assay developed had good reproducibility, linearity and specificity 
and can be used to measure MPA concentrations in saliva. 
 
Overview of the Pharmacokinetic data 
 A total of 33 patients were recruited for the study from May 2013 to March 2014. 
Three patients refused to stay for the total duration of the study (12 hours) and thus were 
excluded from the study. Of the 30 patients recruited, 15 patients were diagnosed as class IV 
lupus nephritis, 2 patients each were class II and III, 1 patient was class V while the rest were 
unclassified. For the pharmacokinetic analysis of total MPA, 12 hour profiles from the 30 
patients (who completed the total 12 hours specimen collection) were analysed using 
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Pmetrics, which was loaded into R, as described in the methods section. For the correlation 
between saliva MPA at and free MPA concentrations at 1 hour, only 28 samples were 
available for analysis (two were below the lower limit of quantification). 
 All the patients had achieved steady state at the time of sampling. The patient 
characteristics have been tabulated in table 10 below.  
Table 9: Patient characteristics 
PARAMETER VALUE* 
TOTAL PATIENTS 30 
AGE 29.33 (18-63) 
SEX (M/F) 4/26 
WEIGHT 55.03 (38-73) 
DOSE PER DAY (mg/day) 1441.67 (500-3250) 
SERUM CREATININE 1.02 (0.46-3.15) 
ALBUMIN 4#(2.8-4.6) 
ESTIMATED GFR 88.98#(23.82-169) 
DOSE PER KG BODY WEIGHT 26.474(8.62-63.83) 
* All values in Mean (Min-Max) format, #-Median values 
 The table below shows the basic pharmacokinetic parameters of the collected data. 
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Table 10: Basic pharmacokinetic parameters of the collected data 
PARAMETER VALUE* 
AUC 0-12 HR(mg.h/L) 45.12 (19.52-67.66) 
Cmax (µg/ml) 16.703(5.243-30.861) 
Tmax(h) 1.083(0.5-2.5) 
C0 (µg/ml) 1.74 (0.17-5.1) 
AUC/DOSE 1.83 (0.97-3.81) 
C0/DOSE 0.069 (0.006-0.153) 
 * All values in Mean (Min-Max) format unless specified otherwise 
 In the above table, Cmax refers to the maximum concentration of MPA achieved in 
plasma. Tmax refers to the time taken to reach Cmax in plasma. C0 refers to the pre-dose 
concentrations of MPA. In this study, the mean Tmax was calculated to be 1.08 hours while 
the mean Cmax was calculated to be 16.70 µg/ml.  
The calculated coefficient of variation for the dose normalized AUC and C0 were 
34.04 % and 61.81 % respectively. 
Figure 16 shows the actual pharmacokinetic profiles of the study patients. Here the 
observation refers to the concentrations of MPA in µg/ml. 
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Figure 16: Observed Pharmacokinetic profiles of the study patients 
 
  
74 
 
Development of a Limited Sampling Strategy (LSS) for MPA AUC0-12Hour 
 The correlations between the MPA AUC0-12 hr and the concentrations at different time 
points are depicted in table 12: 
Table 11: Correlations between the different MPA concentration and MPA AUC0-12 hr 
 AUC0-12hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spearman's 
rho 
C0 Correlation 
Coefficient 
0.630** 
Sig. (2-tailed) 0.000 
C0.5 Correlation 
Coefficient 
0.106 
Sig. (2-tailed) 0.577 
C1 Correlation 
Coefficient 
0.585** 
Sig. (2-tailed) 0.001 
C1.5 Correlation 
Coefficient 
0.781** 
Sig. (2-tailed) 0.000 
C2 Correlation 
Coefficient 
0.647** 
Sig. (2-tailed) 0.000 
C2.5 Correlation 
Coefficient 
0.442* 
Sig. (2-tailed) 0.014 
C3 Correlation 
Coefficient 
0.572** 
Sig. (2-tailed) 0.001 
C4 Correlation 
Coefficient 
0.670** 
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In the above table, C0 – C12 refer to the MPA concentrations at that time point. The 
best correlation was found between MPA AUC0-12 hr and C1.5 as evident from the above table.  
After checking AUC0-12Hr for normality using Kolmogrov Smirnov Test (p>0.200), 
stepwise multiple linear regression was performed using MPA concentrations at Trough, 0.5, 
1, 1.5, 2, 2.5, 3 and 4 hour as the dependent variables in the initial model. 
The final model included only MPA concentrations at trough, 1 Hr, 2 Hr and 4 Hr 
even though the correlation was highest between the concentration at 1.5 hours and the MPA 
AUC0-12 hr. The ANOVA (Analysis of variance) statistics for the stepwise regression is given 
in table 13. In this table, at step 1, all the parameters described in the paragraph above are 
included in the regression model and then sequentially, MPA concentrations at 2.5, 3, 1.5 and 
0.5 hours (Hr2.5, Hr3, Hr1.5, Hr0.5) are excluded from the model from step 2-5 of the 
stepwise multiple linear regression.  
 
  
Sig. (2-tailed) 0.000 
C6 Correlation 
Coefficient 
0.570** 
Sig. (2-tailed) 0.001 
C8 Correlation 
Coefficient 
0.472** 
Sig. (2-tailed) 0.009 
C12 Correlation 
Coefficient 
0.486** 
Sig. (2-tailed) 0.006 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Table 12: ANOVA table for stepwise multiple regression   
STEP PARAMETERS 
EXCLUDED 
DF DEVIANCE RESIDUAL
DF 
RESIDUAL 
DEVIATION 
AIC 
1    21 371.3781 93.48070 
2 - Hr2.5 1 1.835819 22 373.2139 91.62863 
3 - Hr3 1 2.225865 23 375.4398 89.80702 
4 - Hr1.5 1 7.125949 24 382.5657 88.37109 
5 - Hr0.5 1 16.559094 25 399.1248 87.64231 
DF= Degrees of Freedom, AIC= Akaike information criteria 
Table 14 shows the final model coefficients. The PR (>|T|) Column shows the significance of 
each of the individual variables in predicting the AUC0-12Hr.  The residual standard error on 
25 degrees of freedom (df) was 3.996. The multiple r squared for the final model was 0.9266 
while the adjusted r squared based on the degrees of freedom was calculated as 0.9149. The 
overall p-value was 8.23e-14.  
Table 13: Final Model Coefficients 
 ESTIMATE  STD. 
ERROR 
 T VALUE  PR(>|T|)     
(INTERCEPT)  12.5425      2.0016    6.266  1.48e-06 *** 
TROUGH         2.8087      0.7158    3.924  0.000602 *** 
HR1            0.8245      0.1091    7.560  6.49e-08 *** 
HR2            0.8266      0.2117    3.905  0.000632 *** 
HR4              4.6335      0.4912    9.434  1.03e-09 *** 
Significance codes:  0, ‘***’ 0.001, ‘**’0.01, ‘*’0.05, ‘.’ 0.1, ‘ ’1 
Thus, the final regression model equation is as follows:  
MPA AUC0-12	hr = 12.5425 + (2.8087×C0) + (0.8245×C1) + (0.8266×C2) + (4.6335×C4)   
The effect of the individual variables on the AUC0-12 hr is given in the figure below (figure 
17). 
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Figure 17: Model Effects plot for the final regression model 
 
 
The final model residuals are given in table 15. Here, 1Q and 3Q refer to the 1st and the 
3rdquantiles respectively. 
Table 14: Final Model residuals 
    MIN       1Q   MEDIAN      3Q      MAX  
-7.0817  -2.5749   0.2253   2.2756  7.3124  
 
The residuals were tested for heteroskedasticity using the Breusch-Pagan test. One of the 
assumptions that needs to be satisfied for linear modelling includes the absence of 
heteroskedasticity which is nothing but the different variability’s within subpopulations of the 
modelled data. There are many methods to check for heteroskedasticity, however the method 
chosen in this study is the studentized Breusch-Pagan test as it is easy to perform on R and is 
universally accepted. 
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Studentized Breusch-Pagan test 
BP = 4.118, df = 4, p-value = 0.3903 
Result: Null hypothesis that the variances among the residuals was equal was retained. 
The model diagnostics for the final model including the Q-Q plot for the residuals is given in 
the figure below. 
Figure 18: Model diagnostics for the final regression model 
 
Thus, from the Q-Q plot, it was confirmed that the residuals did not grossly violate the 
assumption of normality. The above graph also shows the plot between the residuals and the 
estimated (fitted) AUC values. The bottom right part of the figure shows a plot between the 
residuals and the leverage and also features the Cook’s distance. In regression analysis, 
leverage and Cook’s distance both indicate those observations that are far away from the 
average corresponding predictor values. Cook’s distance is also a measure of the changes in 
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regression coefficients when an observation is deleted. In this study, very few values had a 
high leverage indicating that the regression performed was robust. 
 
 
Validation of the LSS 
 Bootstrap validation was done for the data using 1000 iterations . 
The results of the bootstrap is given in table below: 
Table 15: Bootstrap for the regression model 
 R ORIGINAL BOOTBIAS BOOTSE BOOTMED 
1  INTERCEPT 1000 12.54250 -0.0670279 1.60696 12.33757 
2 TROUGH 1000 2.80874 0.2217399 1.12874 2.90130 
3  HR1 1000 0.82448 -0.0026863 0.11447 0.83048 
4 HR2 1000 0.82656 -0.0375554 0.23863 0.79454 
5 HR4 1000 4.63350 0.0363167 0.63612 4.51556 
 Here, R= No. of iterations, SE= Standard Error, MED= Median values, Trough, HR1, Hr2, Hr4 are MPA 
concentrations at that particular time point. 
Therefore, Post bootstrap, the final regression model for the LSS to predict MPA AUC0-12Hr 
is as follows: 
MPA AUC0-12Hr = 12.3376 + (2.9013×C0) + (0.8305×C1) + (0.7945×C2) + (4.5156×C4)   
Here, C0, C1, C2, C4 refer to the MPA concentrations at that particular time point. 
                  After the bootstrap, the MPA AUC0-12Hr was estimated using the post bootstrap 
equation as mentioned above. The Prediction bias and the Absolute prediction error were 
calculated as mentioned in the methods section. The overall prediction bias was found to be -
0.13% (95 % confidence interval [CI]: -3.49, 3.23) while the absolute prediction error was 
7.09% (95 % CI: 5.08, 9.10). Apart from this, the mean as well as the difference of the 
observed and predicted MPA AUC0-12Hr were calculated and plotted as described by Bland 
and Altman.(57) The plot is shown in figure 19. 
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Figure 19: Bland Altman Plot for agreement between Observed and Predicted AUC values 
 
            Mean difference 
……..  +/- 1 SD from mean difference 
------ +/- 2 SD from mean difference 
 
 This Bland Altman plot shows a good agreement between the 
observed and predicted MPA AUC0-12 hr. It also rules out the presence of a systematic error in 
the findings due to the random nature of the points. 
The table below tabulates the difference between the actual and the predicted values of AUC 
in our patients. 
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Table 16: Observed and Predicted AUC's and their Difference 
Observed 
AUC 
Predicted AUC Difference between the Observed 
and Predicted AUC 
32.87 31.71 -1.16 
42.85 44.82 1.96 
43.92 39.49 -4.43 
44.78 44.27 -0.51 
46.39 42.99 -3.40 
48.64 53.38 4.75 
50.13 55.92 5.80 
64.15 62.65 -1.50 
67.67 68.57 0.90 
20.83 24.41 3.58 
22.30 23.14 0.84 
29.29 28.54 -0.75 
36.45 43.04 6.59 
39.71 36.02 -3.69 
40.95 34.13 -6.82 
53.22 54.75 1.53 
56.76 48.51 -8.25 
61.46 55.00 -6.44 
63.95 62.88 -1.06 
63.96 64.78 0.82 
65.38 61.33 -4.05 
33.91 32.03 -1.88 
36.48 42.06 5.58 
41.65 39.05 -2.60 
44.75 46.78 2.03 
45.88 46.35 0.47 
53.24 51.39 -1.85 
19.52 22.07 2.55 
28.26 27.70 -0.56 
54.31 51.51 -2.80 
 
 From table 17, it is evident that the predicted AUC and observed 
AUC are in close agreement and reporting of the predicted AUC would result in a decision by 
the clinician which is no different from that of the TDM report with the observed AUC. Thus 
the 4 point LSS is a suitable alternative to measuring the full MPA AUC.  
 Intraclass correlation (ICC) was also performed on the above data. The results 
of the ICC are tabulated in table 18. The ICC is used to assess the consistency of 
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measurements made by multiple observers or multiple methods of measuring the same 
quantity. It is similar to the Pearson correlation but with the important difference of the ICC 
using pooled mean and standard deviation for each values while Pearson correlation uses 
individual means and standard deviations. 
 
 
Table 17: Intraclass Correlation between the observed and predicted MPA AUC 
 INTRACLASS 
CORRELATION 
95% CONFIDENCE INTERVAL 
Lower 
Bound 
Upper Bound 
AVERAGE 
MEASURES 
0.981 0.960 0.991 
 
 
Pharmacokinetics of MMF in adult patients with Lupus Nephritis 
The data set was analysed using Pmetrics for R as detailed in the methods section. 
The model file is a FORTRAN code file which is required for Pmetrics to analyse the data. 
The model used was an oral 2 compartment model with variable parameters including Ka, 
Ke, V, KPC, KCP and Tlag (for explanation of each term, see paragraph below table 19). The 
program was run 28 times with a combination of various primary variables until the model 
with acceptable coefficient of determination (R2>0.90). Given below is the model file used 
for the analysis: 
#Pri 
Ke, 0, 1.5 
V, 0.01, 80 
Ka, 0.4, 10 
KCP, 0, 3.5 
KPC, 0, 0.35 
Tlag1, 0, 1 
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FA1, 0.6, 0.99 
 
#COV 
WT 
DPKG 
ALB 
GFR 
CREAT 
 
#F 
FA(1)=FA1 
 
#SEC 
CL=Ke*V*GFR 
 
#Lag 
TLAG(1) = Tlag1 
 
#Out 
Y(1) = X(2)/V 
 
#Err 
L=0.1 
0.1, 0.15,0,0 
 
The model file is divided into different blocks, each preceded by a # sign. The blocks 
used in this model included primary (#Pri), fraction absorbed (#F), covariates (#Cov), 
secondary variables (#Sec), absorption lag (#Lag), Output equation in FORTRAN code 
(#Out) and a lambda error block (#Err) for the MPA assay error polynomials. The covariates 
included in our model were serum albumin (ALB), dose per Kg body weight (DPKG), body 
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weight (WT), estimated glomerular filtration rate by modified MDRD (modification of diet in 
renal disease) method (GFR) and serum creatinine levels (CREAT). 
The non-parametric adaptive grid method was used to analyse the data which is 
inbuilt in Pmetrics for R. The model parameters are summarized in the table below. 
Table 18: Pharmacokinetic parameters of the study 
PK 
PARAMETERS 
MEAN SD MEDIAN 
Ke 0.421 0.348 0.338 
V 21.299 13.450 20.015 
Ka 3.906 3.114 2.714 
KCP 1.317 0.707 1.137 
KPC 0.052 0.057 0.037 
TLAG1 0.356 0.289 0.355 
  
 In the above table, Ke refers to the elimination rate constant while Ka is the absorption 
rate constant. Tlag1 is the time lag for oral absorption of MMF. KCP and KPC refers to the 
shift of MMF from the central to the peripheral compartment and vice versa. V refers to the 
volume of distribution of MMF. The apparent volume of distribution (V/F where F is the 
fraction of MMF absorbed) for all patients from the table is 21.3 ±	13.45litres. The apparent 
clearance (CL/F) of MMF was estimated to be 8.97 L/Hr. The individual prediction 
characteristics of the model is given in the figure below (figure 20). 
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Figure 20: Individual prediction characteristics of the 2-compartment model for MMF 
 
 The individual predictions had a coefficient of determination r2 of 0.915. The bias of 
the individual predictions were also relatively low (-0.103). The model had an imprecision of 
0.699 which is acceptable. The figure below shows the marginal density plots of the 
individual primary variables in the model. 
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Figure 21: Marginal density plots for the primary variables of the model 
 
 The figure below (figure 22) shows the individual observed as well as the model 
predicted pharmacokinetic profiles of the 30 patients. The unbroken line corresponds to the 
actual measured MPA concentration-time curve while the black round dots indicate the 
model predicted values at the time points at which the MPA specimens were collected as 
mentioned in the methods section. The time is set from 48 to 60 hours to indicate that all the 
patients had achieved steady state at the time of sampling and due to restriction on the inputs 
in the comma separated values (.csv) files into the Pmetrics program.  
 
 
 
 
 
87 
 
 
 
Figure 22: Individual observed and model predicted concentration time curves (continued on next 3 pages) 
–– 
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Free MPA, Saliva MPA and total MPA 
 The table given below tabulates the statistical descriptions of the various data 
collected. All required data was available for 28 patients including the serum albumin level. 
The values of the total, free and saliva MPA is in µg/ml. The free fraction is calculated as 
free MPA divided by the total MPA at 1 hour post dose. 
Table 19: Descriptive statistics of Free and Saliva MPA at 1 Hour 
 N Range Minimum Maximu
m 
Mean 
Total MPA at 1 Hr 28 26.221 2.029 28.250 12.05836 
Saliva MPA at 1 Hr 28 0.329 0.008 0.337 0.07861 
Free MPA at 1 Hr 28 0.508 0.012 0.520 0.12839 
Albumin 28 1.8 2.8 4.6 3.907 
Free Fraction 28 3.93 0.15 4.08 1.1345 
 
 
Correlations between total, free and saliva MPA 
 Spearman correlation was first performed on the whole data set and the results of the 
correlation are tabulated in table 21 
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Table 20: Spearman correlation for free MPA as well as Saliva MPA 
 TOTAL MPA 
CONCENTRATION 
AT 1 HR 
SALIVA MPA 
CONCENTRATION 
AT 1 HR 
FREE MPA 
CONCENTRATION 
AT 1 HR 
FREE 
(UNBOUND) 
FRACTION 
OF MPA 
TOTAL MPA 
CONCENTRATION 
AT 1 HR 
Correlation 
Coefficient 
1.000 .322 .600** -.033 
Sig. (2-
tailed) 
 .094 .001 .866 
N 28 28 28 28 
SALIVA MPA 
CONCENTRATION 
AT 1 HR 
Correlation 
Coefficient 
.322 1.000 .085 -.137 
Sig. (2-
tailed) 
.094  .667 .488 
N 28 28 28 28 
FREE MPA 
CONCENTRATION 
AT 1 HR 
Correlation 
Coefficient 
.600** .085 1.000 .736** 
Sig. (2-
tailed) 
.001 .667  .000 
N 28 28 28 28 
FREE (UNBOUND) 
FRACTION OF MPA 
Correlation 
Coefficient 
-.033 -.137 .736** 1.000 
Sig. (2-
tailed) 
.866 .488 .000  
N 28 28 28 28 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 From this table (table 21), it is evident that in our study group, there is a statistically 
significant correlation between free MPA at 1 hour and the free fraction (r=0.736) as also 
between free MPA and the total MPA at 1 hour (r=0.60). There was no statistically 
significant correlation between the saliva MPA at 1 hour with either free or total MPA 
at 1 hour or the free fraction.  
The study populations into two groups depending upon albumin level (Serum Albumin<3.5 
as group 1 while >=3.5 was group 2). There were 8 patients in group 1 and 20 in group 2. The 
descriptive statistics are tabulated in table 22. The mean free fraction was higher in group 1 
than in group 2. 
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Table 21: Descriptive statistics of total free and MPA saliva at 1 hour as well as the free fraction of MPA 
GROUP  N MINIMU
M 
MAXIMU
M 
MEAN STD. 
DEVIATIO
N 
1 Total MPA 
Concentration at 1 Hr 
8 5.005 20.070 11.4033 6.082359 
Saliva MPA 
concentration at 1 Hr 
8 0.008 0.107 0.04050 0.036688 
Free MPA 
Concentration at 1 Hr 
8 0.039 0.520 0.20825 0.155184 
GFR 8 25.96 142.09 90.4462 35.37737 
Free (Unbound) 
fraction of MPA 
8 0.41 4.08 1.9767 1.39008 
2 Total MPA 
Concentration at 1 Hr 
20 2.029 28.250 12.3203 7.224631 
Saliva MPA 
concentration at 1 Hr 
20 0.010 0.337 0.09385 0.090421 
Free MPA 
Concentration at 1 Hr 
20 0.012 0.267 0.09645 0.070378 
GFR 20 23.82 169.00 87.4110 36.33914 
Free (Unbound) 
fraction of MPA 
20 0.15 1.72 0.7976 0.37154 
  
 From this table, it is evident that the saliva MPA and the free MPA concentrations in 
plasma were higher in the group with low albumin as compared to those having normal 
albumin level. 
 Results of the group wise spearman correlation are tabulated in table 22. The results 
were very different from the whole data set. It was seen that the correlations between saliva 
MPA at 1 hour and the free (r=0.790) as well as the total MPA (r=0.786) at 1 hour correlated 
well in the low albumin group while it was not so in the normal albumin group. In the normal 
albumin group, the statistically significant correlations included that between the free MPA in 
Plasma at 1 hour and free fraction (r=0.579) as well as the total MPA at 1 hour (r=0.720). 
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Table 22: Spearman Correlations between low (1) and normal (2) albumin groups 
GROUP     TOTAL 
MPA 
CONCENT
RA-TION 
AT 1 HR 
SALIVA MPA 
CONCENTRAT
I-ON AT 1 HR 
FREE MPA 
CONCENTRAT
I-ON AT 1 HR 
FREE 
FRACTIO
N OF MPA 
1 Total MPA 
Concentratio
n at 1 Hr 
Correlation 
Coefficient 
1.000 .786* .599 -.238 
Sig. (2-
tailed) 
 .021 .117 .570 
Saliva MPA 
concentration 
at 1 Hr 
Correlation 
Coefficient 
.786* 1.000 .790* .238 
Sig. (2-
tailed) 
.021  .020 .570 
Free MPA 
Concentratio
n at 1 Hr 
Correlation 
Coefficient 
.599 .790* 1.000 .623 
Sig. (2-
tailed) 
.117 .020  .099 
Free 
(Unbound) 
fraction of 
MPA 
Correlation 
Coefficient 
-.238 .238 .623 1.000 
Sig. (2-
tailed) 
.570 .570 .099  
2 Total MPA 
Concentratio
n at 1 Hr 
Correlation 
Coefficient 
1.000 .111 .720** -.062 
Sig. (2-
tailed) 
 .640 .000 .796 
Saliva MPA 
concentration 
at 1 Hr 
Correlation 
Coefficient 
.111 1.000 -.070 -.242 
Sig. (2-
tailed) 
.640  .769 .305 
Free MPA 
Concentratio
n at 1 Hr 
Correlation 
Coefficient 
.720** -.070 1.000 .579** 
Sig. (2-
tailed) 
.000 .769  .008 
Free 
(Unbound) 
fraction of 
MPA 
Correlation 
Coefficient 
-.062 -.242 .579** 1.000 
Sig. (2-
tailed) 
.796 .305 .008  
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Prediction of Free MPA 
Using Saliva  
To answer the question of predicting free concentration of MPA using a non-invasive 
method of saliva MPA assay, a multiple linear regression analysis was performed. Both 
albumin and the dose of MMF per kg body weight were includes as predictors in the model. 
The results of the regression are tabulated in the table below. 
Table 23: Model Summary for Regression model to predict free MPA 
Model R 
Square 
Adjusted 
R Square 
Std. Error 
of the 
Estimate 
Change Statistics 
R Square 
Change 
F 
Change 
df1 df2 Sig. F 
Change 
1 .371 .293 .093550 .371 4.725 3 24 .010 
a. Predictors: (Constant), Albumin, DPKG, Saliva MPA concentration at 1 Hr 
b. Dependent Variable: Free MPA Concentration at 1 Hr 
  
 The coefficient statistics for the model are given in table 25. 
 
Table 24: Modela coefficients to predict free MPA 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. 
Error 
Beta 
1 (Constant) .331 .136  2.435 .023 
Saliva MPA 
concentration 
at 1 Hr 
.001 .229 .001 .006 .995 
DPKG .005 .002 .398 2.443 .022 
Albumin -.081 .032 -.428 -2.531 .018 
a. Dependent Variable: Free MPA Concentration at 1 Hr 
 From this table, it is evident that Saliva concentrations at 1 hour was not a 
significant variable in predicting free MPA concentrations at 1 hour.  
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Using Total MPA 
We tried to examine the possibility of estimating free MPA at 1 hour in plasma by 
using total MPA at 1 hour in plasma, dose per Kg body weight of MMF and serum albumin 
levels of the patients using stepwise multiple regression. The table below (table 26) shows the 
ANOVA statistics for the stepwise regression based on the Akiake information criterion 
(AIC) values. 
 The initial model included total MPA at 1 hour (Hr1), serum albumin (Albumin), 
MPA Saliva at 1 hour (Sal1) as well as dose per Kg body weight of MMF (DPKG). The 
ANOVA table (table 24) shows the changes in the AIC values at every step of the stepwise 
multiple regression. Here, step 1 includes the initial model parameters and sequentially, Sal1 
and DPKG are excluded from the model. 
 
Table 25: ANOVA table for regression analysis to determine free MPA from total MPA as well as albumin 
Step Parameters 
Excluded 
Df Deviance Resid. 
Df 
Resid. 
Dev 
AIC 
1    23 0.170 -132.953 
2 - Sal1 1 0.0003 24 0.170 -134.903 
3 - DPKG 1 0.0040 25 0.174 -136.254 
 
 The final model is as follows: 
Free MPA at 1Hr = 0.3715 + (0.0084 X Hr1) - (0.0881 X Albumin) 
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The table below (table 27) gives the summary of the regression model coefficients. 
Table 26: Regression model coefficients for free MPA 
 Estimate Std. 
Error 
t value PR(>|t|) 
(Intercept) 0.371529 0.112042 3.316 0.00279 ** 
Hr1 0.008394 0.002355 3.564 0.00150 ** 
Albumin -0.088134 0.027453 -3.210 0.00362 ** 
Signif. Codes:  0, ‘***’ 0.001, ‘**’ 0.01, ‘*’ 0.05, ‘.’ 0.1, ‘ ’ 1 
Residual standard error: 0.08344 on 25 degrees of freedom 
Multiple R-squared:  0.479, Adjusted R-squared:  0.4373  
F-statistic: 11.49 on 2 and 25 DF, p-value: 0.0002888 
 From table no. 25, we can infer that both total MPA at 1 hour as 
well as serum albumin are significant predictors of free MPA in plasma at 1 hour (P-
value<0.01). The figure (figure 12) below depicts the effect of the individual model 
parameters on free MPA at 1 Hr. The significant negative association between serum albumin 
and free MPA at 1 hour is evident from figure 23 and table 28. 
98 
 
Figure 23: Model effects plot for the individual parameters predicting free MPA at 1 hour 
 
 The table below (table 28) depicts the characteristics of the 
residuals in the model: 
Table 27: Model residuals 
Min 1Q Median 3Q Max 
-0.140481 -0.041375 0.001521 0.021927 0.309124 
 
 However, this equation was found to have a very high precision 
error of 36 %. Thus, TOTAL MPA CANNOT BE USED IN THE PREDICTION OF 
FREE MPA.  
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Discussion 
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Limited Sampling Strategy for MPA AUC0-12 hr 
 This is the first report of development of LSS for MMF in Indian patients with lupus 
nephritis. Our centre has previously published a paper developing a limited sampling strategy 
for patients prescribed Mofilet (Emcure) brand of MMF for renal transplant patients using a 
five point assay which has now translated into routine clinical service for patients.(58) 
Rahman et al observed in a review that the MPA AUC0-12 hr were best predicted when 
concentrations at trough, 1 hour and 3 hour were included in the LSS.(15) Rahman et al 
reported that when the 3 point LSS for MPA was derived using multiple regression analysis, 
the mean bias and precision was 0.8 and 22.6 % respectively.(15) Our study included a 4 
point LSS for patients taking MMF for lupus nephritis. The advantage of our 4 point LSS is 
that it does not compromise on accuracy and precision of MPA AUC and the patient only has 
to remain in the Unit for four hours for collection of the four samples. As evident from table 
15, the LSS predicted AUC measurements did not make a clinical difference as compared to 
the observed MPA AUC0-12 hr. 
 Ting et al in 2006 mentioned that the various acceptable methods for LSS validation 
included  i) Dividing data into a sample set and a validation set (best method), ii) Jackknife 
validation method and iii) Bootstrap method. (59)An earlier  study has used bootstrap to 
validate a LSS for free MPA AUC0-12 hr.(60) 
 Ting et al also mention that LSS developed should ideally have only 3 time points or 
less.(59)  However, by having 3 time points or less for a drug with high inter-individual 
variability, we are bound to miss certain important time points like Tmax (Time taken to reach 
maximum concentration in plasma). Rahman et al also reported in their review that the LSS 
may yield better results if the later time points which account for the enterohepatic 
recirculation of MMF are added into the equation.(15) However, this would require the 
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patient to stay in the laboratory for 6 hours or more and it will not add any further benefit 
except cutting down on the number of samples that need to be collected for the AUC0-12 hr. 
Therefore, we only added concentrations at time points up to 4 hours of MMF administration 
for the development of the LSS so as to accord maximum benefit to the patient with 
minimum interference with regard to the clinical interpretation of the MPA AUC0-12 hr. 
 De Winter et al in 2009 developed 4 equations using multiple regression analysis for 
predicting MPA AUC in patients taking MMF for autoimmune diseases.(42) Their study 
included 26 ANCA associated vasculitis patients and only 12 SLE patients.   
The equations are summarized in the table below (table 29). 
Table 28:de Winter et al developed LSS for MMF in autoimmune diseases(42) 
Equation Validation set 
 Bias (%) RMSE 
(%) 
R2 
AUC = 38.3 + 11.7 X C0 3.4 26.8 0.48 
AUC = 30.8 + 10.1 X C0+ 0.7 X C0.67 4.8 25.1 0.53 
AUC = 17.5 + 7.1 X C0+ 1.0 X C1+ 2.6 X C3 0.8 22.6 0.61 
AUC = 12.3 + 4.7 X C0+ 1.2 X C1+ 2.7 X C3+ 1.8 
X C6 
-0.4 17.3 0.70 
 
 As evident from table 27, including more time points improved the coefficient of 
determination (R2) of the AUC. The four point LSS developed by them had a bias of -0.4 % 
and a root mean square error (RMSE) of 17.3 %. The LSS developed in our study for patients 
on Mycept® had a bias of -0.13 % and an absolute prediction error of 7.09 %. We also tried to 
validate the 3 point equation (using C0, C1 and C3) developed by de Winter (table 29) using 
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our data and the bias was 17.63 % with an absolute prediction error of 19.37 %. Thus, we 
cannot use this equation in our patients with lupus nephritis. Based on the above, it is safe to 
postulate that an LSS developed for a particular population may not be applicable to other 
populations and thus different LSS’s must be validated according to the population in 
question.  
In our hospital patients are also prescribed the enteric coated formulation of 
mycophenolate (Renfor). But it needs to be stressed that the LSS used with MMF cannot be 
applied to enteric coated formulations because of the difference in pharmacokinetic profiles 
between the two. In a previous study done at our centre using enteric coated mycophenolate 
sodium, it was found that the Cmax was much higher (27.6 µg/ml) and mean Tmax was 2.9 
hours. (61) Thus, the LSS developed in our study is bound to miss important time points like 
Tmax for those patients on mycophenolate sodium and thus the estimated AUC will be a lot 
lower than the actual measured AUC. 
Rahman et al reported that  the correlation between AUC and trough concentrations 
were the highest in patients with lupus nephritis taking MMF formulation of MPA (r2 0.90-
0.94).(15) Mino et al, in 2008 had described that MPA trough concentrations had correlated 
very well with MPA AUC0-12 hr in patients taking MMF for lupus nephritis 
(r=0.94,p<0.01).(62) Mino et al reported that a lack of specimen collection at the time of the 
second peak, could have produced a lower observed AUC than the actual. This may have 
contributed to a high correlation between the trough and AUC.  Lertdumrongluk et al also 
reported in their study MMF trough levels correlated well with MPA AUC0-12 hr (r=0.92).(31)  
But this study only included 12 patients with severe lupus nephritis. 
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In a recently published article by Streicher et al, it was noted that pre-dose (trough) 
plasma concentrations might be sufficient to monitor MMF in patients with autoimmune 
diseases, especially SLE.(41) He recommended that a trough concentration from 2.5 to 4.5 
µg/ml would be ideal to prevent clinical flares. However, from our data, it is evident that only 
pre-dose (trough) plasma concentrations of MMF is insufficient to calculate MMF exposure 
(spearman correlation of 0.63). Neumann et al in their study had reported a correlation of 
0.578 between the MPA AUC0-12 hr and the 12 hour trough concentration which is similar to 
that obtained in our study. The question that needs to be addressed is whether trough 
concentration can be the sole parameter in assisting dose alterations by the clinician. So using 
the above mentioned therapeutic range for trough concentration as 2.5-4.5 µg/ml, we found 
that 24 out of 30 patients in our study would require a different decision on the dosing as 
compared to dose individualization based on MPA AUC0-12 hr. 
In the absence of clear cut monitoring practices for the therapeutic drug monitoring for MMF, 
it is still circumspect as to what is the ideal method of monitoring MMF exposure in 
autoimmune diseases like SLE. Further studies are definitely required to define a clear cut 
monitoring practice for MMF in patients with autoimmune diseases.  
The four point LSS developed in this study has an acceptable bias and it is also desirable that 
this LSS be validated on a separate sample of patients before it can be recommended as a 
clinically viable substitute to the full MPA AUC0-12 hr. The other practical reasons that 
support the use of this LSS for MPA AUC0-12 hr estimation is a difference of 50-60 % in the 
cost incurred for the estimation of AUC0-12 using LSS as the number of samples that need to 
be analysed is three times lesser. 
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Pharmacokinetics of MMF in lupus nephritis 
 To my knowledge, there has been no study done on Indian patients to elucidate the 
pharmacokinetics of MMF in adults with lupus nephritis. Earlier studies have compared the 
pharmacokinetics of MMF in patients with autoimmune disease.(12,62) Neumann et al 
elucidated the pharmacokinetics of MMF in autoimmune diseases  and reported mean values 
of MPA AUC0-12 hr and Cmax (70.6 mg.h/L and 21.8 µg/ml respectively) as compared to our 
study (45.12 mg.h/L and 16.7 µg/ml) .(12) The dose used in their study was 2 grams per day. 
All (except three of our patients) were on a dose less than 2 grams per day. 24 of our 30 
patients were on a dose less than or equal to 1500 mg per day. This difference in dosing could 
have contributed to the higher exposure seen in their study in comparison to our study. 
More recent studies like Mino et al have pharmacokinetic parameter values as AUC 
that is similar to that obtained in our study.(62) But the mean Cmax reported by Mino et al was 
5.03 µg/ml as compared to our findings which was 16.7 µg/ml despite the median dose of 
MMF in their study (2gm) which was higher than the mean dose in our study (1.4gm). The 
low Cmax may be attributed to the collection time points (0, 0.5, 1, 2, 5, 8, 12 Hr) in the post 
dose period. Having lesser time points in the early post dose period may have resulted in 
missing the actual Cmax of the profiles.  
A study done in 12 Thai patients with severe lupus nephritis on MMF had mean MPA 
AUC0-12 hr and Cmax of 57.97 mg.h/L and 19.43 µg/ml respectively. The mean trough was 
2.47 µg/ml in their study. The mean dose was 1416.67 mg/day which was comparable to that 
in our patients (1441.67 mg/day).  The lower estimated EGFR values (69.94 v/s 88.98 
ml/min) in their patients may have led to a slightly higher exposure of MPA, trough, Cmax and 
AUC compared to our patients.(31) 
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 In a recent study done in children with SLE, the apparent volume of distribution was 
similar to that in this study (24.8 v/s 21.4 L).(39) However, the apparent clearance seemed to 
be higher in this study in children than in our adult patients (19.2 v/s 8.97 L/h). The probable 
reason for this is that the children have a higher clearance as compared to adults.  
 A previous study by de Winter et al had used a two compartment pharmacokinetic 
model similar to our study and they described values of Tlag (0.287 h) and Clearance (7.92 
L/h) which were close to the corresponding values in our study (0.356 h and 8.97 L/h 
respectively).(42) However, the Volume of distribution in their patients was much higher in 
their study compared to ours (52.4 v/s 21.4 L). 
Correlation between MPA in saliva and free MPA in plasma 
 Mendonza et al had reported in 2006 that except the trough sample, all the other MPA 
samples in saliva correlated well with both the unbound (r=0.910) as well as the bound 
fraction (r=0.909) of MPA.(45) However, in our study set, it was found that the correlation 
was not significant (r=0.085 and 0.322, p>0.05 for unbound and total concentrations in 
plasma) (Table 12). However, when we split the data into 2 groups based on albumin, it was 
found that the correlation became significant in the group with low albumin (r=0.790 
between free and saliva MPA and 0.786 between free and total MPA, p=0.02 for both) (Table 
14). However, there were only 8 patients in the low albumin and probably this needs to be 
investigated in a larger group of patients. In the rest of the patients with normal albumin 
level, there was no significant correlation of free with either saliva or total MPA. 
 There could be various reasons for our results compared with the previous study done 
on the same topic.(45) It sometimes took longer than 5 minutes for the patients to express the 
saliva and thus there could have been an error in sampling of saliva in patients. An avenue 
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that could have been tried was induction of saliva by using lime so that the sampling times 
were strictly adhered to.  
The measurement of (free) unbound concentrations of MPA in plasma is a lot costlier 
as compared to the measurement of the total concentrations because of the requirement of a 
centrifugal filter and also the unbound concentrations are more relevant as compared to total 
in the presence of low albumin concentrations in certain diseases like SLE.(16,17) Therefore, 
we tried to predict the unbound concentrations of MPA in plasma using regression analysis 
with saliva MPA concentrations, serum albumin and dose per Kg body weight of MMF as the 
variables in the equation. But it was noted that the saliva concentrations of MPA in SLE was 
not a significant predictor of unbound concentrations of MPA in plasma in our data set (table 
23).  
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Limitation 
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1) Both clinical outcome and adverse events were not correlated with the pharmacokinetics of 
MMF. This study was conducted only at a single time point and the goals of this study was to 
elucidate the pharmacokinetics of MMF in patients with lupus nephritis. To observe clinical 
outcome and adverse effects related to MPA concentration was beyond the scope of this 
study. To study a clinical outcome, we need to incorporate laboratory and clinical parameters 
both at baseline and a suitable follow up period.  
2) Strict timings while collecting saliva specimens could not be adhered to always as some 
patients could not express adequate saliva within 5 minutes of taking the 1 hour post dose 
blood specimen. Some patients required up to 30 minutes to produce adequate saliva for the 
assay purpose. This may be one of the reasons for the disagreement in the correlation 
between saliva MPA and free MPA in between our findings and an earlier reported study (by 
Mendonza et al). 
3) Both the free MPA and saliva MPA concentrations estimated were in the range of .01-.05 
µg/ml. We used the HPLC for this analysis. We would recommend that in future for a more 
accurate and precise analysis, the LC-MS/MS (if available) may be the instrument of choice 
for this analysis. 
4) The number of patients in the low albumin group was low and not adequate for a 
validation of the results. 
5) The total number of patients in this study was only 30. We are aware that the best 
validation for a model is always on a separate group of patients. So we recommend that more 
number of patients be recruited at a later time for validation of this model. 
 
109 
 
 
 
 
 
Conclusions 
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 This study has, for the first time, described the pharmacokinetics of Mycophenolate 
Mofetil in Indian adult patients with lupus nephritis. We observed a positive correlation 
between saliva and free MPA in patients with low albumin, however this finding needs to be 
validated in more number of patients. This study has also developed a reliable, clinically 
viable limited sampling strategy for MPA AUC0-12 hr in patients taking MMF for lupus 
nephritis using four time points and completed within four hours post dose.  
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Future Scope 
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 The four point limited sampling strategy developed for MMF in patients with 
lupus nephritis needs to be validated in a separate set of patients, before it can 
clinically replace measurement of full 12 hour AUC.  
 
 A well planned randomized clinical trial is required to prove if there is a 
definite benefit to therapeutic drug monitoring of MPA in lupus patients. (one 
group with dose based on clinical outcome and the second group with dosing 
based on TDM ) 
 
 
 Further work needs to be performed to confirm the therapeutic ranges to be 
followed in Indian patients with lupus nephritis.  This needs to have a 
thorough clinical follow up included with TDM.  
 
 The clinical utility of measuring MPA in saliva needs to be ascertained by 
more studies especially in those patients having a low albumin level. 
 
 
 Preferably, the saliva MPA and free MPA concentrations need to be measured 
using a mass spectrometer detector. 
 
 An opportunity exists to create a world wide data base on mycophenolic acid 
for various indications to increase the present knowledge base on the 
pharmacokinetics of MMF. 
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